Cost-Effectiveness Analysis of Older Adult Vaccination with the Bivalent Respiratory Syncytial Virus Prefusion F (RSVpreF) Vaccine in Mexico
Year-round RSVpreF vaccination in Mexico among adults aged 60–99 years could substantially reduce medically attended RSV cases and RSV-related mortality and is projected to be cost-effective, thereby supporting the adoption of preventive strategies to address the growing clinical and economic burden of RSV in Mexico’s...